Skip to Content

Personalized Cancer Therapy

The department is spearheading personalized therapy programs that match patients with targeted drugs based on their tumor's molecular profiles: 

  • PREDICT: Profile-Related Evidence Determining Individualized Cancer Therapy
    Filip Janku, M.D., Ph.D.

  • IMPACT: Initiative for Molecular Profiling and Advanced Cancer Therapy
    Apostolia M. Tsimberidou, M.D., Ph.D.

We now have early evidence that matching patients with targeted drugs in this way can result in response rates that are higher than would be expected without such matching. Our goal is to screen every patient for their tumor's molecular abnormality and use this testing to more choose the best treatment regimen for that individual.

Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R.
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitor.
Mol Cancer Ther. 2011 Jan 7. [Epub ahead of print]

A. M. Tsimberidou, N. G. Iskander, D. S. Hong, J. J. Wheler, S. Fu, S. A. Piha-Paul, A. Naing, G. S. Falchook, F. Janku, R. Luthra, S. Wen, R. Kurzrock.
Personalized medicine in a phase I clinical trials program: The M. D. Anderson Cancer Center Initiative.
J Clin Oncol 29: 2011 (suppl; abstr CRA2500)

Personalized Therapy Conferences

Personalized Cancer Conference - Dr. Razelle Kurzrock discussed "Early Stage Molecular Profiling" at the Worldwide Innovative Networking. 

View Video

2011 ASCO Annual Meeting - Chicago - Dr. Apostolia Tsimberidou discussed "Molecular Profiling Improved Cancer Therapy" 

View Video

Resources

Observer Program 

We offer one short-term observer position each month.  

Appointments & Referrals

For a referral to clinical trials with a new targeted drug, call (713) 792-1160, or visit our Contact Information page.


© 2014 The University of Texas MD Anderson Cancer Center